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1.	  IntroducHon	  
Teratogens	   are	   deﬁned	   as	   diﬀerent	   types	   agents	   (chemical,	   physical,	  
radia7on,	  mechanical,	  infec7ous	  agents)	   	  that	  can	  produce	  morphological	  













A	   clear	   example	   of	   teratogen	   is	   thalidomide,	   which	   administra7on	   to	  
pregnant	   women	   in	   the	   early	   60s	   to	   fade	   typical	   nausea	   and	   vomi7ng,	  
resulted	  in	  thousands	  of	  new-­‐borns	  aﬀected	  with	  phocomelia	  (absence	  of	  
limbs).	   Thalidomide	   is	   used	   nowadays	   to	   treat	   mul7ple	   myeloma,	  
inhibi7ng	  the	  Wnt	  signalling	  pathway.	  
Fig.	   2:	   Schema7c	   representa7on	   of	   the	   rela7on	  
between	  teratogens,	  cancer	  and	  embryonic	  cells.	  
2.	  RelaHon	  cancer-­‐teratogens-­‐development	  
There	   is	   a	   rela7on	   between	   cancer	   cells	   and	   developing	   embryos	  
cells.	  If	  we	  think	  about	  them	  as	  two	  diﬀerent	  7ssues,	  both	  of	  them	  
have	   similar	   characteris7cs,	   and	   teratogens	   strategy	   is	   used	  
because	  of	  these	  similari7es:	  
•  They	  present	  a	  high	  prolifera7ve	  ra7o.	  
•  Both	   of	   them	   ac7vate	   some	   signalling	   pathways	   that	   are	  
inac7vated	  in	  most	  of	  normal	  7ssues.	  
•  They	   can	   change	   their	   phenotype	   and	   carry	   out	   similar	  
movements,	   like	   methastasis	   in	   cancer	   or	   ingression	   during	  
gastrula7on	  in	  embryos.	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4.	  New	  candidate	  for	  research:	  Aminotriazole.	  
•  Used	  in	  farms	  to	  inhibit	  vegetal	  growth.	  
•  It	  is	  mainly	  stored	  in	  young	  7ssues	  and	  7ssues	  with	  high	  prolifera7ve	  ac7vity.	  
•  Causes	  teratogenia	  in	  chicken	  eggs,	  but	  not	  demonstrated	  in	  mammals.	  
•  It	  is	  a	  compe77ve	  inhibitor	  of	  imidazoleglycerol-­‐phosphate	  dehydratase,	  an	  enzyme	  that	  catalyses	  the	  seventh	  step	  of	  his7dine	  produc7on.	  
Tumor	  cells	  are	  in	  a	  high	  prolifera7ve	  cell	  cycle	  status,	  and	  one	  of	  the	  most	  representa7ve	  characteris7cs	  of	  aminotriazole	  is	  the	  fact	  that	  is	  mainly	  stored	  
in	   these	   types	  of	  7ssues.	  Aminotriazole	   could	  be	  a	  poten7al	   candidate	   to	  ﬁnd	  new	   indica7ons	   for	   it	   and	  be	  used	   in	   such	   important	   therapies	  as	  an7	  
tumor.	  
	  
Fig.	   1:	   Example	   of	   how	  
teratogens	   can	   aﬀect	  
development.	   In	   the	  
p i c t u r e ,	   	   s t u ﬀ e d	  
bicephalous	   calf	   at	   the	  
D a r l ow o	   Mu z e um ,	  
Poland.	  
3.1	  Cyclopamine	  
Cyclopamine	   is	   a	   teratogen	   that	   causes	   cyclopia	   in	   sheeps	   and	   its	  
mechanism	   of	   ac7on	   is	   well	   known.	   It	   consists	   to	   inhibit	   the	   Sonic	  
Hedgehog	  signalling	  pathway	  (Hh)	  by	  direct	  interac7on	  and	  inhibi7on	  of	  
Smoothened	   protein,	   leading	   to	   an	   inhibi7on	   of	   the	   pathway.	   This	  
pathway	   is	  overexpressed	   in	  tumor	  cells,	  but	  also	   in	  embryonic	  7ssues.	  
Cyclopamine	  is	  used	  in	  chemotherapy	  to	  treat	  meduloblastoma.	  
Fig.	  3:	  On	  the	  lee,	  Hh	  pathway	  in	  absence	  of	  ligand.	  Hh	  dependent	  genes	  expression	  is	  inhibited	  by	  fragments	  resul7ng	  of	  
the	  Gli	  proteins	  limited	  proteolysis.	  If	  Smoothened	  is	  not	  inhibited,	  Gli	  won’t	  repress	  gene	  expression.	  On	  the	  right,	  the	  
eﬀect	  of	  cyclopamine	  inhibi7ng	  Smoothened	  results	  in	  repression	  of	  expression.	  [3]	  
3.2	  Valproic	  acid	  
Valproic	   acid	   is	   used	   to	   treat	   epilepsy	   and	   bipolar	   disorders.	   It	  
inhibits	   histone	   deacetylase	   HDAC,	   a	   nega7ve	   regulator	   of	   gene	  
expression	  of	  the	  Wnt	  signalling	  pathway,	  which	  is	  very	  important	  
in	  many	  processes,	  like	  prolifera7on,	  growth	  or	  survival,	  and	  mainly	  
ac7vated	   in	   embryonic	   7ssues.	   In	   cancer	   cells	   is	   also	   reac7vated,	  
and	  this	  factor	  is	  very	  important	  in	  tumor	  ini7a7on,	  metastasis	  and	  
most	   of	   the	   hallmarks	   of	   cancer.	   Valproic	   acid	   is	   also	   used	   in	  
combina7on	   with	   re7noic	   acid	   to	   treat	   breast	   cancer	   and	   inhibit	  
tumor	  cell	  prolifera7on.	  
3.3	  ReHnoic	  acid	  
Re7noic	  acid	  has	  a	  totally	  diﬀerent	  mechanism	  of	  ac7on.	  It	  is	  a	  morphogen	  that	  helps	  deﬁning	  the	  anteroposterior	  axis	  and	  its	  eﬀects	  are	  mediated	  by	  
the	  ligand-­‐dependent	  transcrip7on	  factors	  RAR	  and	  RXR.	  They	  regulate	  cell	  prolifera7on	  via	  dose-­‐dependent	  modula7on	  of	  the	  MAPK	  pathway:	  low	  
concentra7ons	   of	   re7noic	   acid	   increases	   EGF	   signalling,	   s7mula7ng	   cell	   prolifera7on,	   but	   higher	   doses	   inhibit	   cell	   division	   by	   decreasing	   ERK1	  
ac7va7on.	  Excess	  of	  re7noic	  acid	  in	  pregnant	  woman	  produces	  underdevelopment	  of	  kidneys	  in	  embryos.	  
Fig.	   4:	   Wnt-­‐dependent	   signalling	   pathway	   in	   both	   ligand	   presence	   and	   absence	   situa7ons.	  
Thalidomide	  and	  Valproic	  acid	  inhibit	  the	  pathway	  with	  two	  diﬀerent	  mechanisms.	  [4]	  
